.Attribute Medicine, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medication conjugate (ADC) tisotumab vedotin led to improved progression-free as well as overall survival, bring about FDA approval as well as a new procedure possibility for clients.